PT95169A - Forma de dosagem para administracao de glipizida hipoglicemica por via oral - Google Patents

Forma de dosagem para administracao de glipizida hipoglicemica por via oral

Info

Publication number
PT95169A
PT95169A PT95169A PT9516990A PT95169A PT 95169 A PT95169 A PT 95169A PT 95169 A PT95169 A PT 95169A PT 9516990 A PT9516990 A PT 9516990A PT 95169 A PT95169 A PT 95169A
Authority
PT
Portugal
Prior art keywords
glipizide
dosage
administration
oral hypoglycemic
hypoglycemic
Prior art date
Application number
PT95169A
Other languages
English (en)
Other versions
PT95169B (pt
Inventor
Patrick S-L Wong
Atul Devdatt Ayer
Anthony L Kuczinski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT95169A publication Critical patent/PT95169A/pt
Publication of PT95169B publication Critical patent/PT95169B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Telephone Function (AREA)
  • Telephonic Communication Services (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT95169A 1989-09-05 1990-08-31 Processo para a preparacao de um dispositivo, para administrar glipizida hipoglicemica por via oral PT95169B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/402,314 US5024843A (en) 1989-09-05 1989-09-05 Oral hypoglycemic glipizide granulation

Publications (2)

Publication Number Publication Date
PT95169A true PT95169A (pt) 1991-05-22
PT95169B PT95169B (pt) 1998-06-30

Family

ID=23591411

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95169A PT95169B (pt) 1989-09-05 1990-08-31 Processo para a preparacao de um dispositivo, para administrar glipizida hipoglicemica por via oral

Country Status (20)

Country Link
US (2) US5024843A (pt)
EP (1) EP0490991B1 (pt)
JP (1) JP2919964B2 (pt)
KR (1) KR0157640B1 (pt)
AT (1) ATE94393T1 (pt)
AU (1) AU632859B2 (pt)
CA (1) CA2024502C (pt)
DE (1) DE69003392T2 (pt)
DK (1) DK0490991T3 (pt)
ES (1) ES2060199T3 (pt)
FI (1) FI104950B (pt)
GR (1) GR1000932B (pt)
HK (1) HK116897A (pt)
IE (1) IE62594B1 (pt)
MX (1) MX171191B (pt)
NO (1) NO303963B1 (pt)
NZ (1) NZ235127A (pt)
PT (1) PT95169B (pt)
WO (1) WO1991003247A1 (pt)
ZA (1) ZA906972B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ATE314054T1 (de) * 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1782798A3 (en) * 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
WO1998023263A1 (en) * 1996-11-25 1998-06-04 Alza Corporation Ascending-dose dosage form
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
WO2001091716A1 (en) * 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
WO2001091717A1 (en) * 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Oral delivery form comprising glipizide
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
CN1729005A (zh) * 2002-11-15 2006-02-01 兰贝克赛实验室有限公司 含双胍－磺酰脲类组合的药物剂型
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
JP2007509971A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン メトホルミンの増加された吸収のための組成物及び投与形態物
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
CN100571783C (zh) * 2006-10-30 2009-12-23 北京红林制药有限公司 格列吡嗪控释片及其制备方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN101940578B (zh) * 2010-08-25 2012-07-25 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
LT3019167T (lt) 2013-07-12 2021-03-25 Knopp Biosciences Llc Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation

Also Published As

Publication number Publication date
JP2919964B2 (ja) 1999-07-19
NO920740D0 (no) 1992-02-25
CA2024502C (en) 1991-03-06
NO303963B1 (no) 1998-10-05
KR920703066A (ko) 1992-12-17
FI920956A0 (fi) 1992-03-04
US5545413A (en) 1996-08-13
FI104950B (fi) 2000-05-15
DE69003392D1 (de) 1993-10-21
DK0490991T3 (da) 1993-11-29
PT95169B (pt) 1998-06-30
CA2024502A1 (en) 1991-03-06
ES2060199T3 (es) 1994-11-16
DE69003392T2 (de) 1994-01-13
IE903166A1 (en) 1991-03-13
GR1000932B (el) 1993-03-16
AU632859B2 (en) 1993-01-14
MX171191B (es) 1993-10-06
ZA906972B (en) 1991-06-26
NO920740L (no) 1992-02-25
JPH05500222A (ja) 1993-01-21
AU6417590A (en) 1991-04-08
KR0157640B1 (ko) 1998-11-16
NZ235127A (en) 1993-02-25
WO1991003247A1 (en) 1991-03-21
EP0490991B1 (en) 1993-09-15
US5024843A (en) 1991-06-18
HK116897A (en) 1997-09-05
EP0490991A1 (en) 1992-06-24
GR900100659A (en) 1992-01-20
ATE94393T1 (de) 1993-10-15
IE62594B1 (en) 1995-02-08

Similar Documents

Publication Publication Date Title
PT95169A (pt) Forma de dosagem para administracao de glipizida hipoglicemica por via oral
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
NO924209L (no) Doseringsform for tilfoersel av et antiparkinsonmiddel
NO306377B1 (no) Doseform for avgivelse av et medikament
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
NO920856D0 (no) Innretning for administrering av medikamenter for slimhinnevev
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
ES2034035T3 (es) Procedimiento de preparacion de una forma farmaceutica para la administracion y/o dosificacion de medicamentos.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
ES1008953Y (es) Un dispositivo para la reconstitucion y administracion de sustancias terapeuticas a pacientes mediante infusion.
DK493887A (da) Buccal formulering

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19901221

FG3A Patent granted, date of granting

Effective date: 19980303

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130304